Galmed gets more time for Nasdaq $1 bid compliance

Galmed Pharmaceuticals Ltd. reports that Nasdaq has granted an additional 180 calendar days, until January 25, 2027, for the company to regain compliance with Nasdaq’s minimum $1 bid price per share requirement.

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. reports that Nasdaq has granted an additional 180 calendar days, until January 25, 2027, for the company to regain compliance with Nasdaq’s minimum $1 bid price per share requirement.

Galmed was first notified on January 29, 2026 that its ordinary shares had traded below $1 for 30 consecutive trading days and did not regain compliance by the initial July 28, 2026 deadline. The company requested and received the extended period. Compliance will be restored if the bid price closes at or above $1 per share for at least 10 consecutive trading days before January 25, 2027. This report is incorporated by reference into Galmed’s existing Form S-8 and Form F-3 registration statements.

Positive

• None.

Negative

• Non-compliance with Nasdaq $1 bid requirement persists after the initial deadline, indicating the company’s shares have traded below $1 for an extended period and remain subject to Nasdaq’s continued listing standards process.

Key Figures

Extended compliance deadline: January 25, 2027 Minimum bid price: $1 per share Initial notice date: January 29, 2026 +3 more

6 metrics

Extended compliance deadline January 25, 2027 New Nasdaq deadline to regain $1 minimum bid price compliance

Minimum bid price $1 per share Nasdaq Listing Rule 5550(a)(2) requirement for ordinary shares

Initial notice date January 29, 2026 Date Nasdaq first notified Galmed of bid price deficiency

Initial compliance period end July 28, 2026 End of first 180-day period to cure bid price deficiency

Trading day requirement 10 consecutive trading days Period the bid must close at or above $1 to regain compliance

Initial non-compliance window 30 consecutive trading days Duration shares traded below $1 before first Nasdaq notice

Key Terms

Nasdaq Listing Rule 5550(a)(2), minimum $1 bid price per share requirement, Registration Statements on Form S-8, Registration Statements on Form F-3

4 terms

Nasdaq Listing Rule 5550(a)(2) regulatory

"under Nasdaq Listing Rule 5550(a)(2) on January 29, 2026"

minimum $1 bid price per share requirement regulatory

"to regain compliance with the Nasdaq’s minimum $1 bid price per share requirement"

Registration Statements on Form S-8 regulatory

"incorporated by reference into the Company’s Registration Statements on Form S-8"

Registration Statements on Form F-3 regulatory

"and the Company’s Registration Statements on Form F-3"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Galmed Pharmaceuticals (GLMD) disclose in its July 2026 Form 6-K?

Galmed disclosed that Nasdaq granted an additional 180 days, until January 25, 2027, for it to regain compliance with the $1 minimum bid price requirement for its ordinary shares after failing to do so by July 28, 2026.

What is the new Nasdaq compliance deadline for GLMD’s $1 minimum bid price?

Nasdaq set January 25, 2027 as Galmed’s new deadline to cure its bid price deficiency. This follows an earlier period ending July 28, 2026, during which the company did not regain compliance with the $1 per share minimum.

How can Galmed Pharmaceuticals (GLMD) regain compliance with Nasdaq’s bid price rule?

Galmed will regain compliance if its ordinary shares’ bid price closes at or above $1 per share for at least 10 consecutive trading days at any time before January 25, 2027, under Nasdaq’s listing rules.

When did Nasdaq first notify GLMD about its minimum bid price deficiency?

Nasdaq first notified Galmed on January 29, 2026 that its ordinary shares failed to meet the $1 minimum bid price requirement after trading below that level for 30 consecutive trading days under Nasdaq Listing Rule 5550(a)(2).

Which registration statements does this GLMD Form 6-K affect?

The report is incorporated by reference into Galmed’s Registration Statements on Form S-8 (including Nos. 333-206292 and 333-227441) and Form F-3 (including Nos. 333-272722 and 333-283241), making the update part of those filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:06 PM Accepted by SEC EDGAR 07/31/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of July 2026

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On July 30, 2026, Galmed Pharmaceuticals Ltd. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is eligible for an additional 180 calendar day period, or until January 25, 2027, to regain compliance with the Nasdaq’s minimum $1 bid price per share requirement.

The Company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1 per share for 30 consecutive trading days under Nasdaq Listing Rule 5550(a)(2) on January 29, 2026, and was given until July 28, 2026 to regain compliance. The Company did not regain compliance with the minimum $1 bid price per share requirement during the first 180-calendar-day compliance period and submitted a written request to the Staff to afford it an additional 180-day compliance period to cure the deficiency.

If at any time before January 25, 2027, the bid price of the Company’s ordinary shares closes at or above $1 per share for a minimum of 10 consecutive trading days, the Company will regain compliance with the Nasdaq Listing Rules, and the matter will be closed.

This Form 6-K is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163, and 333-290399) and the Company’s Registration Statements on Form F-3 (Registration Nos. 333-272722 and 333-283241).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.
Date: July 31, 2026	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer